Does cardiopulmonary bypass still represent a good investment? The biomaterials perspective

    Research output: Contribution to journalArticle

    10 Citations (Scopus)

    Abstract

    Cardiopulmonary (CPB) bypass is 50 years old this year, and has undergone considerable change in that time, particularly with regard to developing technology. However, in recent years the routine application of CPB, as the treatment of choice for patients undergoing reparative heart surgery, has been challenged by new, evolving techniques, particularly Off-Pump Coronary Artery Bypass (OPCAB) and stenting. This paper considers whether CPB still represents a sound investment prospect, with particular emphasis on the biomaterial developments currently taking place. Whilst we accept that routine application of CPB is shrinking under pressure from less invasive techniques, we suggest that this may represent an opportunity to deliever a more highly evolved perfusion to the core of very sick and complex patients who may not be suitable candidates for OPCAB or stenting. These patients will benefit from the application of new technologies currently under development, such as smaller perfusion circuits, improved biomaterial surfaces, smart membranes, and biosensor technology, all aimed at making clinical perfusion a safer and more predictable procedure for the patient. All things conssidered, we feel that CPB, although shrinking in absolute size, still represents a good investment.
    LanguageEnglish
    Pages225-231
    Number of pages6
    JournalPerfusion
    Volume18
    Issue number4
    DOIs
    Publication statusPublished - 2003

    Fingerprint

    Biocompatible Materials
    Cardiopulmonary Bypass
    Biomaterials
    Off-Pump Coronary Artery Bypass
    Perfusion
    Technology
    Pumps
    surgery
    new technology
    candidacy
    Biosensors
    Surgery
    Biosensing Techniques
    Acoustic waves
    Thoracic Surgery
    Membranes
    Networks (circuits)
    Pressure
    time
    Therapeutics

    Keywords

    • cardiopulmonary bypass
    • hemodilution
    • bypass surgery
    • heart
    • medicine

    Cite this

    @article{b0b8983283a642e8b8fa0703ca65ebd4,
    title = "Does cardiopulmonary bypass still represent a good investment? The biomaterials perspective",
    abstract = "Cardiopulmonary (CPB) bypass is 50 years old this year, and has undergone considerable change in that time, particularly with regard to developing technology. However, in recent years the routine application of CPB, as the treatment of choice for patients undergoing reparative heart surgery, has been challenged by new, evolving techniques, particularly Off-Pump Coronary Artery Bypass (OPCAB) and stenting. This paper considers whether CPB still represents a sound investment prospect, with particular emphasis on the biomaterial developments currently taking place. Whilst we accept that routine application of CPB is shrinking under pressure from less invasive techniques, we suggest that this may represent an opportunity to deliever a more highly evolved perfusion to the core of very sick and complex patients who may not be suitable candidates for OPCAB or stenting. These patients will benefit from the application of new technologies currently under development, such as smaller perfusion circuits, improved biomaterial surfaces, smart membranes, and biosensor technology, all aimed at making clinical perfusion a safer and more predictable procedure for the patient. All things conssidered, we feel that CPB, although shrinking in absolute size, still represents a good investment.",
    keywords = "cardiopulmonary bypass, hemodilution, bypass surgery, heart, medicine",
    author = "T. Gourlay and P. Connolly",
    year = "2003",
    doi = "10.1191/0267659103pf667oa",
    language = "English",
    volume = "18",
    pages = "225--231",
    journal = "Perfusion",
    issn = "0267-6591",
    number = "4",

    }

    Does cardiopulmonary bypass still represent a good investment? The biomaterials perspective. / Gourlay, T.; Connolly, P.

    In: Perfusion, Vol. 18, No. 4, 2003, p. 225-231.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Does cardiopulmonary bypass still represent a good investment? The biomaterials perspective

    AU - Gourlay, T.

    AU - Connolly, P.

    PY - 2003

    Y1 - 2003

    N2 - Cardiopulmonary (CPB) bypass is 50 years old this year, and has undergone considerable change in that time, particularly with regard to developing technology. However, in recent years the routine application of CPB, as the treatment of choice for patients undergoing reparative heart surgery, has been challenged by new, evolving techniques, particularly Off-Pump Coronary Artery Bypass (OPCAB) and stenting. This paper considers whether CPB still represents a sound investment prospect, with particular emphasis on the biomaterial developments currently taking place. Whilst we accept that routine application of CPB is shrinking under pressure from less invasive techniques, we suggest that this may represent an opportunity to deliever a more highly evolved perfusion to the core of very sick and complex patients who may not be suitable candidates for OPCAB or stenting. These patients will benefit from the application of new technologies currently under development, such as smaller perfusion circuits, improved biomaterial surfaces, smart membranes, and biosensor technology, all aimed at making clinical perfusion a safer and more predictable procedure for the patient. All things conssidered, we feel that CPB, although shrinking in absolute size, still represents a good investment.

    AB - Cardiopulmonary (CPB) bypass is 50 years old this year, and has undergone considerable change in that time, particularly with regard to developing technology. However, in recent years the routine application of CPB, as the treatment of choice for patients undergoing reparative heart surgery, has been challenged by new, evolving techniques, particularly Off-Pump Coronary Artery Bypass (OPCAB) and stenting. This paper considers whether CPB still represents a sound investment prospect, with particular emphasis on the biomaterial developments currently taking place. Whilst we accept that routine application of CPB is shrinking under pressure from less invasive techniques, we suggest that this may represent an opportunity to deliever a more highly evolved perfusion to the core of very sick and complex patients who may not be suitable candidates for OPCAB or stenting. These patients will benefit from the application of new technologies currently under development, such as smaller perfusion circuits, improved biomaterial surfaces, smart membranes, and biosensor technology, all aimed at making clinical perfusion a safer and more predictable procedure for the patient. All things conssidered, we feel that CPB, although shrinking in absolute size, still represents a good investment.

    KW - cardiopulmonary bypass

    KW - hemodilution

    KW - bypass surgery

    KW - heart

    KW - medicine

    UR - http://dx.doi.org/10.1191/0267659103pf667oa

    U2 - 10.1191/0267659103pf667oa

    DO - 10.1191/0267659103pf667oa

    M3 - Article

    VL - 18

    SP - 225

    EP - 231

    JO - Perfusion

    T2 - Perfusion

    JF - Perfusion

    SN - 0267-6591

    IS - 4

    ER -